Skip to main navigation Skip to search Skip to main content

Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities: A scientific statement of the ESC Council on Basic Cardiovascular Science, the ESC Working Group on Atherosclerosis and Vascular Biology, the ESC Working Group on Cellular Biology of the Heart, the ESC Working Group on Myocardial Function, and the ESC Working Group on Cardiac Cellular Electrophysiology

  • Paul C Evans* (Corresponding Author)
  • , Gemma Vilahur
  • , Petra Kleinbongard
  • , Elena Osto
  • , Carol Ann Remme
  • , Rosalinda Madonna
  • , Dunja Aksentijevic
  • , Harald Sourij
  • , Sean M Davidson
  • , Donato Santovito
  • , Jürgen Gindlhuber
  • , Christian Weber
  • , Wolfgang A Linke
  • , Esther Lutgens
  • , Luc Bertrand
  • , Dana Dawson
  • , Magnus Bäck
  • , G Danilo Norata
  • , Johann Wojta
  • , Cinzia Perrino* (Corresponding Author)
  • *Corresponding author for this work
  • Queen Mary University of London
  • Instituto de Salud Carlos III
  • Institut de Recerca Sant Pau
  • University of Duisburg-Essen
  • Medical University of Graz
  • University of Zurich
  • University of Amsterdam
  • Amsterdam UMC
  • University of Pisa
  • University College London
  • Ludwig Maximilian University of Munich
  • German Centre for Cardiovascular Research
  • Amsterdam UMC
  • University of Münster
  • Mayo Clinic Rochester, MN
  • Université catholique de Louvain
  • Karolinska Institutet
  • Karolinska University Hospital
  • Université de Lorraine
  • University of Milan
  • Medical University of Vienna
  • Ludwig Boltzmann Institute
  • University of Naples Federico II

Research output: Contribution to journal › Article › peer-review

Abstract

Metabolic disorders such as obesity, type 2 diabetes, and dyslipidaemia are major drivers of cardiovascular risk and have reached epidemic levels in Western populations. Recent advances in clinical research have uncovered unexpected and often beneficial effects of pharmacological classes of metabolic drugs on cardiovascular outcomes, revealing complex interactions between metabolism and cardiac pathology. Despite their clinical efficacy, the molecular and cellular mechanisms through which many of these agents act remain only partially understood. This gap in knowledge underscores the urgent need for fundamental research that not only dissects the biology of metabolic disorders and cardiovascular disease but also reveals the mechanistic basis of existing and emerging therapies, thereby enabling rational therapeutic development. This scientific statement, developed by researchers from the European Society of Cardiology (ESC) Council on Basic Cardiovascular Science and several ESC Working Groups, provides a state-of-the-art overview of the emerging molecular and cellular pathways linking metabolic abnormalities with vascular and cardiac disease. By illuminating these critical connections and unresolved questions, this article aims to catalyse innovation in the prevention and management of cardiovascular disease in the context of metabolic dysfunction and to suggest new directions for future research.

Original languageEnglish
Number of pages18
JournalEuropean Heart Journal
Early online date6 Mar 2026
DOIs
Publication statusE-pub ahead of print - 6 Mar 2026

Data Availability Statement

No data were generated or analysed for or in support of this paper.

Funding

P.C.E. is supported by the British Heart Foundation (RG/19/10/34506). G.V. is supported by a Grant PID2021-128891OB-I00 and PLEC2021–007664- NextGenerationEU funded by MCIN/AEI/10.13039/501100011033 and Fondo Europeo de Desarrollo Regional (FEDER) A way of making Europe. This article is based upon work from COST Action, CA22169 EU-METAHEART (GV, PK) supported by COST (European Cooperation in Science and Technology). E.O. is supported by the Swiss National Science Foundation PRIMA: PR00P3_179861/1 and the Swiss Life Foundation, the Heubergstiftung, the Philhuman Stiftung, Novartis Foundation and the Swiss Heart Foundation (FF 19111}, Switzerland. R.M. is supported by the Italian Ministry of University and Research under PNRR - M4C2-I1.3 Project PE_00000019 ‘HEAL ITALIA’, PRIN 2022 Prot. 2022S74XWB and PNRR-NRR-MR1-2022-12376879} S.D. is supported by the British Heart Foundation (PG/21/10798), UK. C.A.R. is supported by the Netherlands CardioVascular Research Initiative (CVON-PREDICT2 2018-30) and the European Joint Research Program on Rare Diseases (EJP-RD; Joint Transnational Call 2020). E.L. is supported by the LeDucq Foundation (CHECKPOINT ATHERO consortium, 22CVD02). W.A.L. is supported by the German Research Foundation (Li 690/14-1). D.D. is supported by the British Heart Foundation (PG/24/11930, FS/CRTF/23/24508, FS/CRTF/22/24275, BHF PG/22/11117, FS/RTF/20/30009, NH/19/1/34595), the National Institute for Health and Care Research Health Technology Assessment (NIHR157523), and Tenovus Scotland (G23.03, G24.07). L.B. is supported by grants from the Fonds National de la Recherche Scientifique (FNRS, Belgium). C.P. is supported by Italian Ministry of Health (PNRR- MR1-2022-12376858), Italian Ministry of University and Research (2020YRETTX_003) and grant CN00000041 ‘National Center for Gene Therapy and Drugs based on RNA Technology’ (concession number 1035 of 17 June 2022-PNRR MUR - M4C2 - Investment 1.4 Call ‘National Centers’, financed by EU- NextGenerationEU, project code (CUP) E63C22000940007).

FundersFunder number
British Heart FoundationRG/19/10/34506, PG/21/10798, PG/24/11930, FS/CRTF/23/24508, FS/CRTF/22/24275, BHF PG/22/11117, FS/RTF/20/30009, NH/19/1/34595
National Institute for Health and Care ResearchNIHR157523
Tenovus ScotlandG23.03, G24.07
European Regional Development FundPID2021-128891OB-I00, PLEC2021–007664- NextGenerationEU
Ministerio de Ciencia e Innovación
Agencia Estatal de Investigación
European Cooperation in Science and TechnologyCA22169 EU-METAHEART
Swiss National Science FoundationPRIMA: PR00P3_179861/1
Swiss Heart FoundationFF 19111
Ministero dell'università e della ricercaPE_00000019, PRIN 2022 Prot. 2022S74XWB, PNRR-NRR-MR1-2022-12376879
Netherlands CardioVascular Research InitiativeCVON-PREDICT2 2018-30
European Joint Research Program on Rare Diseases
Leducq Foundation22CVD02
German Research FoundationLi 690/14-1
Fonds National de la Recherche Scientifique
Ministero della SalutePNRR- MR1-2022-12376858
Ministero dell'università e della ricerca2020YRETTX_003, CN00000041
NextGenerationEUE63C22000940007

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Obesity
    • Metabolic disorders
    • Metabolism
    • Incretin-based therapies
    • Cardiovascular disease

    Fingerprint

    Dive into the research topics of 'Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities: A scientific statement of the ESC Council on Basic Cardiovascular Science, the ESC Working Group on Atherosclerosis and Vascular Biology, the ESC Working Group on Cellular Biology of the Heart, the ESC Working Group on Myocardial Function, and the ESC Working Group on Cardiac Cellular Electrophysiology'. Together they form a unique fingerprint.

    Cite this